イングランドのNHSトラストにおける医薬品カーボンフットプリント、2021-2024年：情報公開請求を用いた縦断研究
Medicine carbon footprinting across National Health Service trusts in England, 2021-2024: a longitudinal study using Freedom of Information requests (原題)
H. A. Taylor, Nazneen Rahman
🤖 gxceed AI 要約
日本語
イングランドのNHSトラスト196機関を対象に、医薬品カーボンフットプリント（MCF）算定の実態を2021年と2024年に情報公開請求で調査した。算定実施は178中30から182中46へ増えたが依然少数で、支出ベース算定では排出係数が中央値の-31%〜+258%と大きくばらつき、推計値に大きな差が生じた。国家ガイダンスによる標準化と製品レベル手法の活用が医薬品脱炭素化に必要と結論づけた。
English
Using Freedom of Information requests to 196 English NHS trusts in 2021 and 2024, this study assessed medicine carbon footprint (MCF) practices. Calculation remained uncommon (30/178 in 2021; 46/182 in 2024), and spend-based emission factors varied widely (-31% to +258% vs median), producing substantially different estimates. The authors call for national guidance on spend-based methods and greater use of standardised product-level approaches.
Unofficial AI-generated summary based on the public title and abstract. Not an official translation.
📝 gxceed 編集解説 — Why this matters
日本のGX文脈において
Scope 3算定の標準化と開示一貫性という課題は、SSBJ基準や有報でのScope 3開示を進める日本企業・医療機関にも共通する。排出係数選択のばらつきが推計値に与える影響は、日本でのサプライチェーン排出量算定の精度管理に示唆を与える。
In the global GX context
This study speaks directly to the global push for consistent Scope 3 accounting under ISSB/CSRD and the challenge of spend-based estimation. It provides rare longitudinal evidence on disclosure consistency in a public healthcare system, relevant to any jurisdiction grappling with supply-chain emissions methodology.
👥 読者別の含意
🔬研究者:Scope 3算定における排出係数選択の不確実性と経年変化を定量化した希少な縦断研究。
🏢実務担当者:支出ベース算定の係数選択が結果を大きく左右するため、算定手法の文書化と一貫性確保が重要。
🏛政策担当者:国家レベルの算定ガイダンス整備がScope 3開示の比較可能性向上に不可欠であることを示す。
📄 Abstract（原文）
Introduction Medicines account for 20% of the National Health Service (NHS) carbon footprint, but it is unclear how consistently they are measured by individual NHS trusts. This study assessed medicine carbon footprint (MCF) practices across NHS trusts in England and whether these changed between 2021 and 2024. Methods Freedom of Information requests were sent to NHS trusts about MCF practices in 2021 and 2024. Responses were analysed to determine the proportion of trusts calculating MCFs, the medicines included and the emission factors used for spend-based calculations. Reported spend-based factors were compared with the median factor for each year to assess the effect of factor choice on MCFs. Results Of 196 trusts included in analysis, 178 (91%) responded for 2021 and 182 (93%) for 2024. Among responding trusts, 30 of 178 calculated MCFs in 2021 compared with 46 of 182 in 2024. Spend-based medicine footprinting increased from 19 trusts in 2021 to 31 in 2024. Ten different factors were used by 15 trusts in 2021 and 13 by 21 trusts in 2024. Reported factors ranged from 31% below to 258% above the median in 2024. Conclusions Medicine carbon footprinting remained uncommon, with only one-quarter of responding NHS trusts calculating a footprint in 2024. Among trusts using spend-based methods, wide variation in emission factors produced substantially different estimated MCFs. Clear national guidance on spend-based methodology could improve consistency in the short term, while greater use of standardised product-level approaches may better support medicine decarbonisation over time.
🔗 Provenance — このレコードを発見したソース
- openalex https://doi.org/10.64898/2026.10.09.26365120first seen 2026-10-14 05:10:28
🔔 こうした論文の新着を逃したくない方は キーワードアラート に登録（無料・3キーワードまで）。
gxceed は公開メタデータに基づく研究支援データセットです。要約・翻訳・解説は AI 支援で生成されています。 最終的な解釈・検証は利用者が原典資料に基づいて行うことを前提とします。